<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2743">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01492400</url>
  </required_header>
  <id_info>
    <org_study_id>206207-024</org_study_id>
    <nct_id>NCT01492400</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal
      implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular
      edema (DME).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Average Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The average BCVA is calculated across study visits for each patient. A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Foveal Thickness Measured by Optical Coherence Tomography (OCT) in the Study Eye</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>OCT is a laser based non-invasive diagnostic system providing high-resolution imaging sections of the fovea (part of the retina) in the study eye after pupil dilation. A negative change from baseline indicates an improvement (less foveal thickness) and a positive change from baseline indicates a worsening (more foveal thickness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Area of Macular Leakage in the Study Eye Measured on Fluorescein Angiography (FA)</measure>
    <time_frame>Baseline, Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>FA is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. A negative change from baseline indicates a decrease in leakage (improvement) and a positive change from baseline indicates an increase in leakage (worsening).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>dexamethasone Intravitreal Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ranibizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone Intravitreal Implant</intervention_name>
    <description>Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.</description>
    <arm_group_label>dexamethasone Intravitreal Implant</arm_group_label>
    <other_name>Ozurdex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.</description>
    <arm_group_label>ranibizumab</arm_group_label>
    <other_name>Lucentis®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 1 or 2 diabetes mellitus

          -  Diagnosis of macular edema

          -  Visual acuity between 20/200 to 20/40

        Exclusion Criteria:

          -  Eye surgery to the study eye within 3 months

          -  Use of Ozurdex® within 9 months

          -  Any active ocular inflammation and infection

          -  Diagnosis of glaucoma

          -  Use of anti-VEGF treatment (e.g., Lucentis®) within 3 months in the eye or systemic
             use (e.g., Avastin®) within 6 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahaus</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>England</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>January 21, 2015</lastchanged_date>
  <firstreceived_date>December 13, 2011</firstreceived_date>
  <firstreceived_results_date>January 21, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone Intravitreal Implant</title>
          <description>Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.</description>
        </group>
        <group group_id="P2">
          <title>Ranibizumab</title>
          <description>Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="182"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Miscellaneous Reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal Reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone Intravitreal Implant</title>
          <description>Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.</description>
        </group>
        <group group_id="B2">
          <title>Ranibizumab</title>
          <description>Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="181"/>
                <measurement group_id="B2" value="182"/>
                <measurement group_id="B3" value="363"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;45 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>45 to 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="102"/>
                <measurement group_id="B2" value="96"/>
                <measurement group_id="B3" value="198"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="74"/>
                <measurement group_id="B2" value="81"/>
                <measurement group_id="B3" value="155"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
                <measurement group_id="B2" value="66"/>
                <measurement group_id="B3" value="135"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="112"/>
                <measurement group_id="B2" value="116"/>
                <measurement group_id="B3" value="228"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye</title>
        <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The average BCVA is calculated across study visits for each patient. A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone Intravitreal Implant</title>
            <description>Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab</title>
            <description>Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="181"/>
                  <measurement group_id="O2" value="182"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Average Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye</title>
            <description>BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The average BCVA is calculated across study visits for each patient. A positive number change from baseline indicates an improvement and a negative number change from baseline indicates a worsening.</description>
            <units>Letters</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60.2" spread="9.74"/>
                  <measurement group_id="O2" value="60.4" spread="9.34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at 12 Months</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.34" spread="7.342"/>
                  <measurement group_id="O2" value="7.60" spread="6.735"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Foveal Thickness Measured by Optical Coherence Tomography (OCT) in the Study Eye</title>
        <description>OCT is a laser based non-invasive diagnostic system providing high-resolution imaging sections of the fovea (part of the retina) in the study eye after pupil dilation. A negative change from baseline indicates an improvement (less foveal thickness) and a positive change from baseline indicates a worsening (more foveal thickness).</description>
        <time_frame>Baseline, Month 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone Intravitreal Implant</title>
            <description>Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab</title>
            <description>Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="181"/>
                  <measurement group_id="O2" value="182"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Foveal Thickness Measured by Optical Coherence Tomography (OCT) in the Study Eye</title>
            <description>OCT is a laser based non-invasive diagnostic system providing high-resolution imaging sections of the fovea (part of the retina) in the study eye after pupil dilation. A negative change from baseline indicates an improvement (less foveal thickness) and a positive change from baseline indicates a worsening (more foveal thickness).</description>
            <units>Microns</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="465.1" spread="136.09"/>
                  <measurement group_id="O2" value="471.2" spread="139.51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Month 12 (N=163, 166)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-173.9" spread="129.64"/>
                  <measurement group_id="O2" value="-163.5" spread="161.34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Area of Macular Leakage in the Study Eye Measured on Fluorescein Angiography (FA)</title>
        <description>FA is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. A negative change from baseline indicates a decrease in leakage (improvement) and a positive change from baseline indicates an increase in leakage (worsening).</description>
        <time_frame>Baseline, Month 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat: all randomized patients</population>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone Intravitreal Implant</title>
            <description>Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab</title>
            <description>Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="172"/>
                  <measurement group_id="O2" value="177"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Total Area of Macular Leakage in the Study Eye Measured on Fluorescein Angiography (FA)</title>
            <description>FA is a technique for examining the circulation of the retina (and detecting any leakage) using a dye-tracing method. Photographs are taken with a specialized low-power microscope with an attached camera designed to photograph the interior of the eye, including the retina and optic disc. A negative change from baseline indicates a decrease in leakage (improvement) and a positive change from baseline indicates an increase in leakage (worsening).</description>
            <units>Square Millimeters (mm^2)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.2" spread="13.01"/>
                  <measurement group_id="O2" value="18.9" spread="12.55"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline at Month 12 (N=125, 142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-16.1" spread="11.64"/>
                  <measurement group_id="O2" value="-12.0" spread="10.54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Treatment emergent adverse events (TEAE) are reported and include all adverse events (AEs) and serious adverse events (SAEs) that began or worsened after study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone Intravitreal Implant</title>
          <description>Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.</description>
        </group>
        <group group_id="E2">
          <title>Ranibizumab</title>
          <description>Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Aortic Valve Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Ventricular Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Hearing Loss</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Open Angle Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Choroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Local Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Atypical Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Infected Bites</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bladder Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lung Squamous Cell Carcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Mantle Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma of the Tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Meningorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Respiratory Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac Pacemaker Insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Liposuction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Peripheral Vascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Cataract Subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vitreous Floaters</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Ocular Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Diabetic Retinal Oedema</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vitreous Detachment</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Punctate Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Macular Oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head,</name_or_title>
      <organization>Allergan, Inc</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
